trending Market Intelligence /marketintelligence/en/news-insights/trending/2FjClxIyX8ZvpH4osXVQgg2 content esgSubNav
In This List

Johnson & Johnson to terminate license for Medivir's hepatitis C drug

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Johnson & Johnson to terminate license for Medivir's hepatitis C drug

Medivir AB said Johnson & Johnson will terminate its license for hepatitis C treatment Olysio, also sold under the brand name Sovriad in Japan.

The Swedish company said Johnson & Johnson unit Janssen Pharmaceuticals Inc. made the decision after assessing the market demand for Olysio, or simeprevir.

The termination will become effective in June 2018, and Medivir will continue to receive royalties on any remaining sales of Olysio until then.

Medivir said it will seek potential commercialization partners for specific territories.